Ocugen licenses gene therapy for blindness to MENA via Roots Pharma

Ocugen, the NASDAQ-listed gene therapy company, has signed a binding term sheet to license OCU400, its modifier gene therapy for retinitis pigmentosa (RP), exclusively to Roots Pharmaceutical and its strategic partner Al-Dhow International Holding, covering the entire Middle East and North Africa region. The deal structure includes upfront and near-term development payments of up to $4 million, cumulative sales milestones of up to $255 million, and a 22% royalty on net sales. Ocugen retains manufacturing and supply responsibilities under a parallel supply agreement.

The arrangement is not yet a finalised contract. The parties expect to execute a definitive licence and supply agreement within 90 days, and material terms could change or the deal could fall away entirely. That caveat aside, the term sheet signals a calculated strategic move: Ocugen is using regional licensing to fund continued development of OCU400 as it navigates a capital-intensive Phase 3 programme.

A therapy targeting an underserved genetic disease burden

Retinitis pigmentosa is a progressive, hereditary disease that destroys photoreceptor cells in the retina, eventually causing blindness. Globally, it is estimated to affect roughly one in 4,000 people, but prevalence is meaningfully higher across parts of the MENA region, where consanguineous marriage patterns elevate rates of autosomal-recessive inherited conditions. For a gene therapy platform, that demographic reality translates directly into addressable market density.

What sets OCU400 apart from conventional gene replacement approaches is its "modifier gene therapy" mechanism. Rather than substituting a single defective gene, it targets a nuclear hormone receptor intended to rebalance the broader gene networks implicated in photoreceptor degeneration. The company describes the approach as gene-agnostic, positioning it to treat RP regardless of which of the dozens of causative mutations a patient carries. Ocugen's Phase 3 liMeliGhT trial is ongoing, with a topline data readout expected in the first quarter of 2027, to be followed by a biologics licence application (BLA) to the US Food and Drug Administration.

The MENA licensing model and its cross-sector implications

For Disrupts readers, the more strategically interesting dimension is the deal architecture itself. Ocugen is not simply selling a product into a new geography; it is using a regional partner with existing rare-disease infrastructure, Roots Pharmaceutical backed by Al-Dhow International Holding, to bear the commercialisation burden in a market it could not cost-effectively penetrate alone. That model is increasingly common among mid-sized US biotech companies that lack the balance sheets to run global commercial operations while simultaneously financing late-stage clinical programmes.

The MENA angle sits within a broader capital reallocation trend. Gulf sovereign wealth funds and regional holding companies have been actively diversifying into life sciences and healthcare infrastructure, drawn by demographic pressures, ageing populations, high rates of hereditary disease, and governments seeking to reduce dependence on medical tourism. Al-Dhow's participation here is a small data point in that larger pattern. As Gulf states invest in biomanufacturing capacity and rare-disease access programmes, deals like this one multiply: a US innovator provides the science; a regional partner provides the distribution network, regulatory relationships, and, increasingly, local capital.

There is a secondary implication worth noting for investors tracking gene therapy as an asset class. The BLA submission for OCU400 has not yet been filed, meaning the $255 million milestone figure is a ceiling that requires both regulatory approval and commercial traction to materialise. With the Phase 3 readout still six to nine months away, the near-term economics lean heavily on the $4 million in upfront and development payments. For a company of Ocugen's size, the licensing structure preserves runway while the pivotal trial concludes, a capital-efficiency trade-off that smaller gene therapy developers increasingly cannot avoid.

The broader question the deal raises is whether the MENA region is becoming a meaningful early-access route for advanced therapies that face reimbursement headwinds in Europe and the US. If OCU400 wins regulatory approval and achieves commercial uptake in the Gulf before securing NICE or CMS coverage, it would add a new variable to the conventional rare-disease commercialisation playbook.